Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

THX PHARMA : Corrected press release : THX Pharma and the Beyond Batten Disease…

This press release cancels and replaces the one issued on September 8, 2026, at 6:00 p.m., which contained a clerical error – the Rare Pediatric Disease Designation (RPDD) granted to the legacy product BBDF-101 cannot apply to the Batten-1 drug candidate. The corrected press release is reproduced in full below…

Lumibird signs a share purchase agreement for the sale of Lumibird Medical to…

Lannion, 8 September 2026 – 22:30 LUMIBIRD SIGNS A SHARE PURCHASE AGREEMENT FOR THE SALE OF LUMIBIRD MEDICAL TO IPG Photonics Corporation Following the entry into exclusive negotiations on July 16, 2026, and the completion of the information-consultation process with employee representative bodies, the Lumibird Group announces the signing, on…

Klea Holding confirms the gradual resumption of operations at Smart Salem and…

Paris, 8 September 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group whose ambition is to capitalise on the strong economic growth in the Middle East to maximise the growth and value creation of its businesses, provides an update on the recovery seen at its subsidiary Smart Salem in Dubai and its strategic progress…

THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a…

A patent jointly owned by BBDF, Baylor College of Medicine and Cardiff University, and exclusively licensed worldwide to THX Pharma Protection in Europe through July 2041, complementing THX Pharma's proprietary formulation patent and the orphan drug designations granted in Europe and the United States Lyon, France – Austin, Texas, USA – September 8, 2026 – 6:00 p…

Klea Holding provides an update on the imminent launch of its operations in…

Paris, 7 September 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group whose ambition is to capitalise on the strong economic growth in the Middle East to maximise the growth and value creation of its businesses, provides an update on the expected opening of the 1st digital medical centre in Riyadh (Saudi Arabia) by its subsidiary Smart Health…

BASTIDE : Revenue for 2025-2026, excluding the impact of the sale of EXPERF: EUR…

Caissargues, September 3, 2026 Groupe Bastide, a leading European provider of home healthcare services, has published its annual revenue for 2025-2026. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no longer includes revenue from EXPERF, which was sold on June 1, 2026…

THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3…

Lyon, France – Austin, Texas, USA – Gentilly, France – September 1, 2026 – 6:00 p.m. CEST – THX Pharma (Theranexus), an innovative biopharmaceutical company developing treatments for rare neurological diseases, together with its partners, the Beyond Batten Disease Foundation (BBDF) and Biocodex, today announced the submission of regulatory…

LUMIBIRD: Photonics confirms strong growth with a 15.3% increase in the first…

PHOTONICS CONFIRMS STRONG GROWTH WITH A 15.3% INCREASE IN THE FIRST HALF OF 2026 Consolidated revenue rose by 7.4% (9.7% on a like-for-like basis) The LUMIBIRD Group (FR0000038242 – LBIRD) reported consolidated revenue of €114.7 million for the first half of 2026, up 7.4% (+9.7% at constant scope and exchange rates)…

Lumibird strengthens its position in strategic laser technologies

LUMIBIRD STRENGTHENS ITS POSITION IN STRATEGIC LASER TECHNOLOGIES Sale of Lumibird's stake in Cilas Long-term industrial partnership with Cilas Lumibird takes over Laser MégaJoule's maintenance operations Against a backdrop of accelerating defense investment in Europe and a growing need for technological sovereignty, Lumibird continues to implement…

Oxurion expands its clinical research platform through strategic biometrics…

Leuven, BELGIUM – July 21, 2026 – 8:00 am CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announced that its subsidiary Axiodis CRO has entered into a strategic partnership with KYomed INNOV & CEISO, a French clinical CRO specializing in digital health and medical device clinical research…

DMS GROUP : Q2 2026 REVENUE: EUR 12.2 MILLION

A penalizing market environment in Radiology in H1 2026, temporarily impacted by the global context and by the postponement of the last deliveries of equipment under the contract in Ukraine Strong momentum in the Bone Densitometry business, with Q2 2026 revenue up 32% 2026 guidance confirmed: DMS Group expects to continue outperforming the medical…

LUMIBIRD ENTERS INTO EXCLUSIVE NEGOTIATIONS FOR THE SALE OF ITS MEDICAL DIVISION…

Lannion, 16 July 2026 – 11:00 pm LUMIBIRD ENTERS INTO EXCLUSIVE NEGOTIATIONS FOR THE SALE OF ITS MEDICAL DIVISION TO IPG Photonics Corporation A defining milestone in Lumibird's development, creating two focused leaders for the next stage of their growth. Following receipt of a binding offer, Lumibird Group announces today that it has entered into…

KLEA HOLDING : Smart Salem records a strong rebound in activity in June 2026…

Paris, 15 July 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group whose ambition is to capitalize on the strong economic development of the Middle East to maximize the growth and value creation of its businesses, reports its revenue for the first half of 2026 and provides an update on the development of its activities…

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…

Leuven, BELGIË – 14 juli 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparantiekennisgeving op 10 juli 2026 van Atlas…

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – July 14, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 10, 2026, from Atlas Special Opportunities II, LLC…

THX Pharma Reports Cash Position as of June 30, 2026

Lyon, France – July 9, 2026 – 6:00 p.m. CET – THX Pharma (Theranexus), an innovative biopharmaceutical company focused on the treatment of rare neurological diseases, today announced its cash position as of June 30, 2026. As of June 30, 2026, available cash amounted to €17.5 million, compared with pro forma cash of €19…

OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer)…

OXURION : Information on the Total Number of Voting Rights (Denominator)…

LUMIBIRD: 2026 first-half results: photonics strong growth and improved…

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…

KLEA HOLDING : Klea Pharmaceuticals secures its first order and reaffirms its…

THX PHARMA : Corrected press release : THX Pharma and the Beyond Batten Disease…

Lumibird signs a share purchase agreement for the sale of Lumibird Medical to…

Klea Holding confirms the gradual resumption of operations at Smart Salem and…

THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a…

Klea Holding provides an update on the imminent launch of its operations in…

BASTIDE : Revenue for 2025-2026, excluding the impact of the sale of EXPERF: EUR…

THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3…

LUMIBIRD: Photonics confirms strong growth with a 15.3% increase in the first…

Lumibird strengthens its position in strategic laser technologies

Oxurion expands its clinical research platform through strategic biometrics…

DMS GROUP : Q2 2026 REVENUE: EUR 12.2 MILLION

LUMIBIRD ENTERS INTO EXCLUSIVE NEGOTIATIONS FOR THE SALE OF ITS MEDICAL DIVISION…

KLEA HOLDING : Smart Salem records a strong rebound in activity in June 2026…

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

THX Pharma Reports Cash Position as of June 30, 2026